By Raffaele Pereno – PhD, MBA LISBON, Portugal – Nerai Bioscience, a biotechnology company spun out from the University of Zurich and ETH Zurich, is working to make gene editing therapies more efficient, more precise, and scalable for rare disease patients. By combining artificial intelligence, high-throughput protein engineering, and CRISPR-based...

CHARLESTOWN, Mass. — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted Orphan...

PHILADELPHIA, PA & BOSTON, Mass. — Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today announced it will present new data at the 29th annual American Society of Gene and Cell Therapy (ASGCT) meeting, taking place May 11-15, in Boston, MA. The Company also announced...